Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial-Reference-Cited by-同舟云学术

Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial

Published:2018-10-31 Issue:10 Volume:13 Page:e0206722
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Satirapoj Bancha^ORCID,Watanakijthavonkul Khanin,Supasyndh Ouppatham

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference26 articles.

1. Epidemiological study of chronic kidney disease progression: a large-scale population-based cohort study;P Vejakama;Medicine (Baltimore),2015

2. Prevalence and Management of Diabetic Nephropathy in Western Countries;B Satirapoj;Kidney Dis (Basel),2015

3. Nephropathy in diabetes;B Satirapoj;Adv Exp Med Biol,2012

4. Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice;M Abe;Curr Drug Metab,2011

5. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence;M Diamant;Drugs,2003

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pioglitazone treatment mitigates cardiovascular bioprosthetic degeneration in a chronic kidney disease model;Frontiers in Pharmacology;2024-08-08

2. Protective effects of pioglitazone in renal ischemia–reperfusion injury (RIRI): focus on oxidative stress and inflammation;Clinical and Experimental Nephrology;2024-06-27

3. Effect of pioglitazone on proteinuria and cardiovascular events in patients with diabetic nephropathy;Journal of Renal Injury Prevention;2023-08-05

4. 2023 UPDATE: Luso-Brazilian evidence-based guideline for the management of antidiabetic therapy in type 2 diabetes;Diabetology & Metabolic Syndrome;2023-07-19

5. Efficacy of 3 months of additional pioglitazone treatment in type 2 diabetes patients with alcoholic fatty liver disease;Diabetology International;2023-02-18